The DOI matches its Crossref record; 72 of the 72 references it cites were found in a registry or an index.
Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients With COVID-19 (April 2020)
Open accessAbstract
Background: There are many pharmacologic therapies that are being used or considered for treatment of coronavirus disease 2019 (COVID-19). There is a need for frequently updated practice guidelines on their use, based on critical evaluation of rapidly emerging literature. The objective was to develop evidence-based rapid guidelines intended to support patients, clinicians, and other healthcare professionals in their decisions about treatment and management of patients with COVID-19. Methods: The Infectious Diseases Society of America (IDSA) formed a multidisciplinary guideline panel of infectious disease clinicians, pharmacists, and methodologists with varied areas of expertise. Process followed a rapid recommendation checklist. The panel prioritized questions and outcomes. Then a systematic review of the peer-reviewed and gray literature was conducted. The Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach was used to assess the certainty of evidence and make recommendations. Results: The IDSA guideline panel agreed on 7 treatment recommendations and provided narrative summaries of other treatments undergoing evaluations. Conclusions: The panel expressed the overarching goal that patients be recruited into ongoing trials, which would provide much-needed evidence on the efficacy and safety of various therapies for COVID-19, given that we could not make a determination whether the benefits outweigh harms for most treatments.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Gautret, P., Lagier, J.-C., Parola, P., Hoang, V. T., Meddeb, L., Mailhe, M., Doudier, B., Courjon, J., Giordanengo, V., Vieira, V. E., et al. (2020) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2020.105949 · Cited by 5,288
RetractedClinical characteristics of coronavirus disease 2019 in China
Guan, W.-J., Ni, Z.-Y., Hu, Y., Liang, W.-H., Ou, C.-Q., He, J.-X., Liu, L., Shan, H., Lei, C.-L., Hui, D. S. C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2002032 · Cited by 30,246 · cited 1×
“The first cases of coronavirus disease 2019 (COVID-19) were reported from Wuhan, China in early December 2019 [1], now known to be caused by a novel beta-coronavirus, named as Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).”
Cochrane Handbook for Systematic Reviews of Interventions: Cochrane Book Series
(2008) · doi:10.1002/9780470712184 · Cited by 25,048
Chen, N., Zhou, M., Dong, X., Qu, J., Gong, F., Han, Y., Qiu, Y., Wang, J., Liu, Y., Wei, Y., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30211-7 · Cited by 21,415
Hoffmann, M., Kleine-Weber, H., Schroeder, S., Krüger, N., Herrler, T., Erichsen, S., Schiergens, T. S., Herrler, G., Wu, N.-H., Nitsche, A., et al. (2020) · Cell · doi:10.1016/j.cell.2020.02.052 · Cited by 20,286
Wu, Z., & McGoogan, J. M. (2020) · JAMA · doi:10.1001/jama.2020.2648 · Cited by 17,016
Cochrane Handbook for Systematic Reviews of Interventions
(2019) · doi:10.1002/9781119536604 · Cited by 14,828
GRADE guidelines: 1. Introduction—GRADE evidence profiles and summary of findings tables
Guyatt, G., Oxman, A. D., Akl, E. A., Kunz, R., Vist, G., Brozek, J., Norris, S., Falck-Ytter, Y., Glasziou, P., & deBeer, H. (2011) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2010.04.026 · Cited by 10,681
Self-citationYang, X., Yu, Y., Xu, J., Shu, H., Xia, J., Liu, H., Wu, Y., Zhang, L., Yu, Z., Fang, M., et al. (2020) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(20)30079-5 · Cited by 10,066
Wu, C., Chen, X., Cai, Y., Xia, J., Zhou, X., Xu, S., Huang, H., Zhang, L., Zhou, X., Du, C., et al. (2020) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2020.0994 · Cited by 8,249
Wang, M., Cao, R., Zhang, L., Yang, X., Liu, J., Xu, M., Shi, Z., Hu, Z., Zhong, W., & Xiao, G. (2020) · Cell Research · doi:10.1038/s41422-020-0282-0 · Cited by 6,958
A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19
Cao, B., Wang, Y., Wen, D., Liu, W., Wang, J., Fan, G., Ruan, L., Song, B., Cai, Y., Wei, M., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2001282 · Cited by 5,187
Ou, X., Liu, Y., Lei, X., Li, P., Mi, D., Ren, L., Guo, L., Guo, R., Chen, T., Hu, J., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-15562-9 · Cited by 3,097
Compassionate Use of Remdesivir for Patients with Severe Covid-19
Grein, J., Ohmagari, N., Shin, D., Diaz, G., Asperges, E., Castagna, A., Feldt, T., Green, G., Green, M. L., Lescure, F.-X., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2007016 · Cited by 2,737
Effective treatment of severe COVID-19 patients with tocilizumab
Xu, X., Han, M., Li, T., Sun, W., Wang, D., Fu, B., Zhou, Y., Zheng, X., Yang, Y., Li, X., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2005615117 · Cited by 2,647
Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma
Shen, C., Wang, Z., Zhao, F., Yang, Y., Li, J., Yuan, J., Wang, F., Li, D., Yang, M., Xing, L., et al. (2020) · JAMA · doi:10.1001/jama.2020.4783 · Cited by 2,277
The IMpact-RSV Study Group (1998) · Pediatrics · doi:10.1542/peds.102.3.531 · Cited by 1,961
Effectiveness of convalescent plasma therapy in severe COVID-19 patients
Duan, K., Liu, B., Li, C., Zhang, H., Yu, T., Qu, J., Zhou, M., Chen, L., Meng, S., Hu, Y., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2004168117 · Cited by 1,960
GRADE guidelines: 2. Framing the question and deciding on important outcomes
Guyatt, G. H., Oxman, A. D., Kunz, R., Atkins, D., Brozek, J., Vist, G., Alderson, P., Glasziou, P., Falck-Ytter, Y., & Schünemann, H. J. (2011) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2010.09.012 · Cited by 1,911 · cited 2×
“Ac ce pt ed M an us cr ipt Question generation Clinical questions were developed into a PICO format (Population, Intervention, Comparison, Outcomes) [5] prior to the first panel meeting.”
Self-citationRole of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings
Chu, C. M. (2004) · Thorax · doi:10.1136/thorax.2003.012658 · Cited by 1,645
Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses
Sheahan, T. P., Sims, A. C., Graham, R. L., Menachery, V. D., Gralinski, L. E., Case, J. B., Leist, S. R., Pyrc, K., Feng, J. Y., Trantcheva, I., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aal3653 · Cited by 1,571
Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys
Warren, T. K., Jordan, R., Lo, M. K., Ray, A. S., Mackman, R. L., Soloveva, V., Siegel, D., Perron, M., Bannister, R., Hui, H. C., et al. (2016) · Nature · doi:10.1038/nature17180 · Cited by 1,556
SARS: systematic review of treatment effects
Stockman, L. J., Bellamy, R., & Garner, P. (2006) · PLoS Medicine · doi:10.1371/journal.pmed.0030343 · Cited by 1,217
Closing the Gap between Methodologists and End-Users: R as a Computational Back-End
Wallace, B. C., Dahabreh, I. J., Trikalinos, T. A., Lau, J., Trow, P., & Schmid, C. H. (2012) · Journal of Statistical Software · doi:10.18637/jss.v049.i05 · Cited by 1,125 · cited 1×
“Where applicable, data were pooled using random effects model (fixed effects model for 2 or less trials or pooling of rates) using RevMan or OpenMeta [7].”
Mair-Jenkins, J., Saavedra-Campos, M., Baillie, J. K., Cleary, P., Khaw, F.-M., Lim, W. S., Makki, S., Rooney, K. D., Convalescent Plasma Study Group, Nguyen-Van-Tam, J. S., et al. (2015) · Journal of Infectious Diseases · doi:10.1093/infdis/jiu396 · Cited by 983
Azithromycin and the Risk of Cardiovascular Death
Ray, W. A., Murray, K. T., Hall, K., Arbogast, P. G., & Stein, C. M. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1003833 · Cited by 954
The convalescent sera option for containing COVID-19
Casadevall, A., & Pirofski, L.-A. (2020) · Journal of Clinical Investigation · doi:10.1172/jci138003 · Cited by 903
de Wit, E., Feldmann, F., Cronin, J., Jordan, R., Okumura, A., Thomas, T., Scott, D., Cihlar, T., & Feldmann, H. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1922083117 · Cited by 887
Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial
Chen, Z., Hu, J., Zhang, Z., Jiang, S., Han, S., Yan, D., Zhuang, R., Hu, B., & Zhang, Z. (2020) · medRxiv · doi:10.1101/2020.03.22.20040758 · Cited by 847
Feltes, T. F., Cabalka, A. K., Meissner, H. C., Piazza, F. M., Carlin, D. A., Top, F. H., Connor, E. M., Sondheimer, H. M., & for the Cardiac Synagis Study Group (2003) · The Journal of Pediatrics · doi:10.1067/s0022-3476(03)00454-2 · Cited by 824
Gautret, P., Lagier, J.-C., Parola, P., Hoang, V. T., Meddeb, L., Sevestre, J., Mailhe, M., Doudier, B., Aubry, C., Amrane, S., et al. (2020) · Travel Medicine and Infectious Disease · doi:10.1016/j.tmaid.2020.101663 · Cited by 765
Molina, J. M., Delaugerre, C., Le Goff, J., Mela-Lima, B., Ponscarme, D., Goldwirt, L., & de Castro, N. (2020) · Médecine et Maladies Infectieuses · doi:10.1016/j.medmal.2020.03.006 · Cited by 749
Establishment and validation of a pseudovirus neutralization assay for SARS-CoV-2
Nie, J., Li, Q., Wu, J., Zhao, C., Hao, H., Liu, H., Zhang, L., Nie, L., Qin, H., Wang, M., et al. (2020) · Emerging Microbes & Infections · doi:10.1080/22221751.2020.1743767 · Cited by 711
[A pilot study of hydroxychloroquine in treatment of patients with moderate COVID-19].
Chen, J., Liu, D., Liu, L., Liu, P., Xu, Q., Xia, L., Ling, Y., Huang, D. F., Song, S., Zhang, D., et al. (2020) · PubMed · doi:10.3785/j.issn.1008-9292.2020.03.03 · Cited by 664
Lee, N., Allen Chan, K. C., Hui, D. S., Ng, E. K. O., Wu, A., Chiu, R. W. K., Wong, V. W. S., Chan, P. K. S., Wong, K. T., Wong, E., et al. (2004) · Journal of Clinical Virology · doi:10.1016/j.jcv.2004.07.006 · Cited by 636
Chan, J. F.-W., Yao, Y., Yeung, M.-L., Deng, W., Bao, L., Jia, L., Li, F., Xiao, C., Gao, H., Yu, P., et al. (2015) · Journal of Infectious Diseases · doi:10.1093/infdis/jiv392 · Cited by 608
Rainsford, K. D., Parke, A. L., Clifford-Rashotte, M., & Kean, W. F. (2015) · Inflammopharmacology · doi:10.1007/s10787-015-0239-y · Cited by 543
In vitro susceptibility of 10 clinical isolates of SARS coronavirus to selected antiviral compounds
Chen, F., Chan, K. H., Jiang, Y., Kao, R. Y. T., Lu, H. T., Fan, K. W., Cheng, V. C. C., Tsui, W. H. W., Hung, I. F. N., & Lee, T. S. W. (2004) · Journal of Clinical Virology · doi:10.1016/j.jcv.2004.03.003 · Cited by 534
Self-citationGS-5734 and its parent nucleoside analog inhibit Filo-, Pneumo-, and Paramyxoviruses
Lo, M. K., Jordan, R., Arvey, A., Sudhamsu, J., Shrivastava-Ranjan, P., Hotard, A. L., Flint, M., McMullan, L. K., Siegel, D., Clarke, M. O., et al. (2017) · Scientific Reports · doi:10.1038/srep43395 · Cited by 513
Kalil, A. C. (2020) · JAMA · doi:10.1001/jama.2020.4742 · Cited by 497
The QT interval in patients with COVID-19 treated with hydroxychloroquine and azithromycin
Chorin, E., Dai, M., Shulman, E., Wadhwani, L., Bar-Cohen, R., Barbhaiya, C., Aizer, A., Holmes, D., Bernstein, S., Spinelli, M., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0888-2 · Cited by 417
Cao, W., Liu, X., Bai, T., Fan, H., Hong, K., Song, H., Han, Y., Lin, L., Ruan, L., & Li, T. (2020) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofaa102 · Cited by 405
Broad-spectrum antivirals for the emerging Middle East respiratory syndrome coronavirus
Chan, J. F. W., Chan, K.-H., Kao, R. Y. T., To, K. K. W., Zheng, B.-J., Li, C. P. Y., Li, P. T. W., Dai, J., Mok, F. K. Y., Chen, H., et al. (2013) · Journal of Infection · doi:10.1016/j.jinf.2013.09.029 · Cited by 385
Joint HFSA/ACC/AHA Statement Addresses Concerns Re: Using RAAS Antagonists in COVID-19
Bozkurt, B., Kovacs, R., & Harrington, B. (2020) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2020.04.013 · Cited by 355
Zhang, X., Donnan, P. T., Bell, S., & Guthrie, B. (2017) · BMC Nephrology · doi:10.1186/s12882-017-0673-8 · Cited by 278
Chronic Hydroxychloroquine Use Associated with QT Prolongation and Refractory Ventricular Arrhythmia
Chen, C.-Y., Wang, F.-L., & Lin, C.-C. (2006) · Clinical Toxicology · doi:10.1080/15563650500514558 · Cited by 270
Human monoclonal antibody as prophylaxis for SARS coronavirus infection in ferrets
ter Meulen, J., Bakker, A. B., van den Brink, E. N., Weverling, G. J., Martina, B. E., Haagmans, B. L., Kuiken, T., de Kruif, J., Preiser, W., Spaan, W., et al. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16506-9 · Cited by 265
Arabi, Y. M., Shalhoub, S., Mandourah, Y., Al-Hameed, F., Al-Omari, A., Al Qasim, E., Jose, J., Alraddadi, B., Almotairi, A., Al Khatib, K., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciz544 · Cited by 248
Macrolide Antibacterials: Drug Interactions of Clinical Significance
von Rosenstiel, N.-A., & Adam, D. (1995) · Drug Safety · doi:10.2165/00002018-199513020-00005 · Cited by 212
Wang, Y., Jiang, W., He, Q., Wang, C., Liu, B., Zhou, P., Dong, N., & Tong, Q. (2020) · medRxiv · doi:10.1101/2020.03.06.20032342 · Cited by 184
Clinical features and progression of acute respiratory distress syndrome in coronavirus disease 2019
Liu, Y., Sun, W., Li, J., Chen, L., Wang, Y., Zhang, L., & Yu, L. (2020) · medRxiv · doi:10.1101/2020.02.17.20024166 · Cited by 172
The journey of remdesivir: from Ebola to COVID-19
Pardo, J., Shukla, A. M., Chamarthi, G., & Gupte, A. (2020) · Drugs in Context · doi:10.7573/dic.2020-4-14 · Cited by 166
Morgan, R. L., Flórez, I. D., Falavigna, M., Kowalski, S. C., Akl, E. A., Thayer, K. A., Rooney, A. A., & Schünemann, H. J. (2018) · Health Research Policy and Systems · doi:10.1186/s12961-018-0330-0 · Cited by 133
Self-citationVoiriot, G., Philippot, Q., Elabbadi, A., Elbim, C., Chalumeau, M., & Fartoukh, M. S. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8060786 · Cited by 128
COVID-19: from epidemiology to treatment
Pericàs, J. M., Meneses, M. H., Sheahan, T. P., Quintana, E., Ambrosioni, J., Sandoval, E., Falces, C., Marcos, M. Á., Tuset, M., Vilella, A., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehaa462 · Cited by 122
Editorial Concern—Possible Reporting of the Same Patients With COVID-19 in Different Reports
Bauchner, H., Golub, R. M., & Zylke, J. W. (2020) · JAMA · doi:10.1001/jama.2020.3980 · Cited by 121
Machavaram, K. K., Almond, L. M., Rostami‐Hodjegan, A., Gardner, I., Jamei, M., Tay, S., Wong, S., Joshi, A., & Kenny, J. R. (2013) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2013.79 · Cited by 111
Steroid therapy and the risk of osteonecrosis in SARS patients: a dose-response meta-analysis
Zhao, R., Wang, H., Wang, X., & Feng, F. (2016) · Osteoporosis International · doi:10.1007/s00198-016-3824-z · Cited by 99
Discontinuation of antimalarial drugs in systemic lupus erythematosus.
Wang, C., Fortin, P. R., Li, Y., Panaritis, T., Gans, M., & Esdaile, J. M. (1999) · PubMed · Cited by 96
Voiriot, G., Dury, S., Parrot, A., Mayaud, C. M., & Fartoukh, M. S. (2010) · CHEST Journal · doi:10.1378/chest.09-3102 · Cited by 94
Genovese, M. C., Kremer, J. M., van Vollenhoven, R., Alten, R., Scali, J. J., Kelman, A., Dimonaco, S., & Brockwell, L. (2017) · Arthritis & Rheumatology · doi:10.1002/art.40176 · Cited by 86
Morgan, N. D., Patel, S. V., & Dvorkina, O. (2013) · JCR Journal of Clinical Rheumatology · doi:10.1097/rhu.0b013e31829d5e50 · Cited by 80
The Ebola clinical trials: a precedent for research ethics in disasters
Calain, P. (2016) · Journal of Medical Ethics · doi:10.1136/medethics-2016-103474 · Cited by 74
Interleukin-6 and cytochrome-P450, reason for concern?
Kim, S., Östör, A. J. K., & Nisar, M. K. (2012) · Rheumatology International · doi:10.1007/s00296-012-2423-3 · Cited by 70
Clinical research ethics for critically ill patients: A pandemic proposal
Cook, D., Burns, K. E. A., Finfer, S. R., Kissoon, N. “., Bhagwanjee, S., Annane, D., Sprung, C. L., Fowler, R. A., Latronico, N., & Marshall, J. C. (2010) · Critical Care Medicine · doi:10.1097/ccm.0b013e3181cbaff4 · Cited by 48
Early observational research and registries during the 2009–2010 influenza A pandemic
Fowler, R., Webb, S. A. R., Rowan, K., Sprung, C. L., Thompson, B., Randolph, A. G., Jouvet, P. A., Lapinsky, S. E., Rubinson, L., Rello, J., et al. (2010) · Critical Care Medicine · doi:10.1097/ccm.0b013e3181d20c77 · Cited by 41
Choosing outcomes for clinical trials: a pragmatic perspective
Iwashyna, T. J., & McPeake, J. M. (2018) · Current Opinion in Critical Care · doi:10.1097/mcc.0000000000000532 · Cited by 20
Lara, P. C., Nguyen, N. P., Macías-Verde, D., Burgos-Burgos, J., Arenas, M., Zamagni, A., Vinh‐Hung, V., Baumert, B. G., Motta, M., Myint, A. S., et al. (2020) · Aging and Disease · doi:10.14336/ad.2020.0506 · Cited by 18
Azithromycin Should Not Be Used to Treat COVID-19
Lighter, J., & Raabe, V. (2020) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofaa207 · Cited by 17
Pneumatosis Intestinalis and Intestinal Perforation in a Patient Receiving Tocilizumab
Jacobs, B., JAWAD, A., & Fattah, Z. (2018) · Archives of Rheumatology · doi:10.5606/archrheumatol.2018.6668 · Cited by 10
Suggestions from Cremona, Italy: 2 months into the pandemic at the frontline of COVID-19 in Europe
Pan, A., Giorgi‐Pierfranceschi, M., Bosio, G., et al. (2020) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2020.05.038 · Cited by 3
Cited by
Extrapulmonary manifestations of COVID-19
Gupta, A., Madhavan, M. V., Sehgal, K., Nair, N., Mahajan, S., Sehrawat, T. S., Bikdeli, B., Ahluwalia, N., Ausiello, J. C., Wan, E. Y., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0968-3 · Cited by 3,185
Mechanisms of SARS-CoV-2 entry into cells
Jackson, C. B., Farzan, M., Chen, B., & Choe, H. (2022) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-021-00418-x · Cited by 3,022
Rosenberg, E. S., Dufort, E. M., Udo, T., Wilberschied, L. A., Kumar, J., Tesoriero, J., Weinberg, P., Kirkwood, J., Muse, A., DeHovitz, J., et al. (2020) · JAMA · doi:10.1001/jama.2020.8630 · Cited by 1,156
Shekerdemian, L. S., Mahmood, N. R., Wolfe, K. K., Riggs, B. J., Ross, C. E., McKiernan, C. A., Heidemann, S. M., Kleinman, L. C., Sen, A. I., Hall, M. W., et al. (2020) · JAMA Pediatrics · doi:10.1001/jamapediatrics.2020.1948 · Cited by 985
Leisman, D. E., Ronner, L., Pinotti, R., Taylor, M. D., Sinha, P., Calfee, C. S., Hirayama, A. V., Mastroiani, F., Turtle, C. J., Harhay, M. O., et al. (2020) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(20)30404-5 · Cited by 855
Metadata
- Authors
- Bhimraj, A., Morgan, R. L., Shumaker, A. H., Lavergne, V., Baden, L., Cheng, V. C.-C., Edwards, K. M., Gandhi, R., Muller, W. J., O’Horo, J. C., Shoham, S., Murad, M. H., Mustafa, R. A., Sultan, S., & Falck-Ytter, Y.
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2020-04-27
- Volume
- 78
- Issue
- 7
- Pages
- e83-e102
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W3019235900
- Cited by
- 1,033
- References
- 72
- FWCI
- 28.19
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.